China Resources Pharmaceutical's subsidiary BOYA BIOLOGY earned 343 million RMB in the first nine months, a decline of 16.8%

AASTOCKS
2025.10.27 14:16

China Resources Pharmaceutical (03320.HK) announced that its subsidiary BOYA BIOLOGY (300294.SZ) achieved a total operating revenue of 1.474 billion RMB for the nine months ending in September, an increase of 18.4% year-on-year. It recorded a net profit of 343 million RMB, a decline of 16.8%

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer